All In Biotech

Drug Trial Radar · NCT00160342

Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes

A Multi-Center, Double-Blind, Placebo-Controlled Comparison of Multiple Doses of Esterified Estrogens and Methyltestosterone, in Combination and Alone, in Relieving Vasomotor Symptoms in Postmenopausal Women

Last checked: Nov 19, 2026Latest source record: Aug 15, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 1,251 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,251

Planned (sponsor's estimate)

Start

Jun 2005

Primary completion

Sep 2007

Study completion Sep 2007

Sponsor

Lead sponsor
Solvay PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Sep 12, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 45 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a research study to evaluate the effectiveness, safety and side effects of several dose levels of esterified estrogens (EE) and methyltestosterone (MT) given individually and in combination compared to a placebo (a tablet with no active drug in it) as a possible treatment for vasomotor symptoms (such as hot flushes and flushing) of menopause. EE and testosterone are two hormones which are typically deficient in menopausal women

Conditions

  • Hot Flushes, Menopause, Postmenopause

Interventions

  • Esterified Estrogens (EE) and Methyltestosterone (MT)Drug

    oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT

  • Esterified Estrogens (EE) and Methyltestosterone (MT)Drug

    oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT

  • Esterified Estrogens (EE) and Methyltestosterone (MT)Drug

    oral tablet, QD, 12 weeks, 0.15 EE/0.30 MT

  • Esterified Estrogens (EE) and Methyltestosterone (MT)Drug

    oral tablet, QD, 12 weeks, 0.30 EE/0.30 MT

  • Esterified Estrogens (EE) and Methyltestosterone (MT)Drug

    oral tablet, QD, 12 weeks, 0.30 EE

  • Esterified Estrogens (EE) and Methyltestosterone (MT)Drug

    oral tablet, QD, 12 weeks, 0.30 EE/0.60 MT

  • Esterified Estrogens (EE) and Methyltestosterone (MT)Drug

    oral tablet, QD, 12 weeks, 0.45 EE

  • Esterified Estrogens (EE) and Methyltestosterone (MT)Drug

    oral tablet, QD, 12 weeks, 0.60 MT

  • Esterified Estrogens (EE) and Methyltestosterone (MT)Drug

    oral tablet, QD, 12 weeks, Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change in frequency of moderate to severe vasomotor symptoms (VMS) from baseline to Week 4Time frame: 4 weeks
  2. Mean change in frequency of moderate to severe VMS from baseline to Week 12Time frame: 12 weeks
  3. Mean change in severity of moderate to severe VMS from baseline to Week 4Time frame: 4 weeks
  4. Mean change in severity of moderate to severe VMS from baseline to Week 12Time frame: 12 weeks

Locations

125 sites in 3 countries. Site status is shown where the registry gives one.

  • Site 37

    Montgomery, Alabama

  • Site 69

    Montgomery, Alabama

  • Site 44

    Tucson, Arizona

  • Site 6

    Jonesboro, Arkansas

  • Site 62

    Little Rock, Arkansas

  • Site 70

    Carmichael, California

  • Site 85

    Carmichael, California

  • Site 87

    Northridge, California

  • Site 18

    San Diego, California

  • Site 27

    San Diego, California

  • Site 54

    San Diego, California

  • Site 31

    Vista, California

  • Site 68

    Walnut Creek, California

  • Site 66

    Denver, Colorado

  • Site 4

    Groton, Connecticut

  • Site 35

    New Britain, Connecticut

  • Site 14

    Waterbury, Connecticut

  • Site 25

    Aventura, Florida

  • Site 26

    Aventura, Florida

  • Site 51

    Clearwater, Florida

  • Site 71

    Clearwater, Florida

  • Site 61

    Daytona Beach, Florida

  • Site 75

    Gainesville, Florida

  • Site 33

    Pensacola, Florida

  • Site 21

    Stuart, Florida

  • Site 82

    Tampa, Florida

  • Site 9

    Venice, Florida

  • Site 83

    West Palm Beach, Florida

  • Site 40

    Alpharetta, Georgia

  • Site 90

    Alpharetta, Georgia

  • Site 23

    Atlanta, Georgia

  • Site 8

    Atlanta, Georgia

  • Site 60

    Powder Springs, Georgia

  • Site 55

    Savannah, Georgia

  • Site 76

    Boise, Idaho

  • Site 64

    Champaign, Illinois

  • Site 58

    Chicago, Illinois

  • Site 72

    Chicago, Illinois

  • Site 74

    Chicago, Illinois

  • Site 50

    Evansville, Indiana

Showing 40 of 125 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.